Investing.com -- Hims Hers Health Inc (NYSE: HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.
The state has opposed the court order to share the expiration dates because they say the dates could reveal the supplier of the drugs, jeopardizing the state's ability to obtain them in the future, ...
PCCA Adds to Its Family of USP Verified Excipient Compounding Bases ...
On Dec. 10, U.S. Rep. Rudy Yakym, Republican of Indiana's 2nd District, and U.S. Rep. André Carson, Democrat of Indiana's 7th ...
AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
To address this, Thermo Fisher Scientific now offers Accelerator Drug Development: a suite of integrated services combining CDMO and CRO capabilities to streamline the drug development journey, from ...
The company says its AI and synthetic biology platform can produce compounds not possible with traditional synthesis ...
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer ...
Here & Now’s Rob Schmitz spoke to STAT health reporter Katie Palmer about the evolution of telehealth, the consumerization of medicine and how the model could drive up health care costs overall.
The Week US on MSN
What is a compounding pharmacy?
Customizing medications can be lifesaving and also dangerous. Understand the advantages and disadvantages of Compounding ...
Nothing corrodes public trust in a regulatory agency faster than the sense that its senior officials are auditioning for ...
2d
Novel compound attacks tuberculosis bacteria's ATP synthase, showing promise against drug resistance
Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback